



(11) **EP 2 175 834 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:  
**Corrected version no 1 (W1 B1)**  
**Corrections, see**  
**Bibliography INID code(s) 84**

(51) Int Cl.:  
**A61K 9/08** *(2006.01)* **A61K 47/26** *(2006.01)*  
**A61K 38/26** *(2006.01)*

(48) Corrigendum issued on:  
**22.08.2012 Bulletin 2012/34**

(86) International application number:  
**PCT/US2008/069473**

(45) Date of publication and mention  
of the grant of the patent:  
**23.02.2011 Bulletin 2011/08**

(87) International publication number:  
**WO 2009/009562 (15.01.2009 Gazette 2009/03)**

(21) Application number: **08772467.0**

(22) Date of filing: **09.07.2008**

(54) **GLP-1-FC FUSION PROTEIN FORMULATION**  
GLP-1-FC FUSIONSPROTEIN-FORMULIERUNG  
FORMULATION DE PROTÉINE DE FUSION GLP-1-FC

(84) Designated Contracting States:  
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR**  
**HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT**  
**RO SE SI SK TR**  
Designated Extension States:  
**AL BA MK RS**

(72) Inventor: **NG, Kingman**  
**Carmel, Indiana 46032 (US)**

(30) Priority: **10.07.2007 US 948855 P**

(74) Representative: **Kent, Lindsey Ruth et al**  
**Eli Lilly and Company Limited**  
**Lilly Research Center**  
**European Patent Operations**  
**Sunninghill Road**  
**Earl Wood Manor**  
**Windlesham**  
**Surrey GU20 6PH (GB)**

(43) Date of publication of application:  
**21.04.2010 Bulletin 2010/16**

(73) Proprietor: **ELI LILLY AND COMPANY**  
**Indianapolis, IN 46285 (US)**

(56) References cited:  
**WO-A-2006/068910**

**EP 2 175 834 B8**